Free Trial

Mustang Bio (MBIO) Competitors

Mustang Bio logo
$1.87 +0.17 (+10.00%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$1.87 +0.00 (+0.05%)
As of 06:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBIO vs. DYAI, MAAQ, GBIO, OKUR, MURA, TPST, MDCX, BDRX, RNTX, and NNVC

Should you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include Dyadic International (DYAI), Mana Capital Acquisition (MAAQ), Generation Bio (GBIO), OnKure Therapeutics (OKUR), Mural Oncology (MURA), Tempest Therapeutics (TPST), Medicus Pharma (MDCX), Biodexa Pharmaceuticals (BDRX), Rein Therapeutics (RNTX), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical products" industry.

Mustang Bio vs. Its Competitors

Dyadic International (NASDAQ:DYAI) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

In the previous week, Dyadic International had 6 more articles in the media than Mustang Bio. MarketBeat recorded 8 mentions for Dyadic International and 2 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.63 beat Dyadic International's score of 0.63 indicating that Mustang Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Dyadic International Positive
Mustang Bio Very Positive

Dyadic International has higher revenue and earnings than Mustang Bio. Dyadic International is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyadic International$3.49M7.07-$5.81M-$0.20-4.10
Mustang BioN/AN/A-$15.75M-$78.00-0.02

Dyadic International has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500.

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 10.0% of Mustang Bio shares are owned by institutional investors. 29.5% of Dyadic International shares are owned by company insiders. Comparatively, 0.2% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Mustang Bio has a net margin of 0.00% compared to Dyadic International's net margin of -163.94%. Mustang Bio's return on equity of 0.00% beat Dyadic International's return on equity.

Company Net Margins Return on Equity Return on Assets
Dyadic International-163.94% -233.69% -59.37%
Mustang Bio N/A N/A -29.49%

Dyadic International presently has a consensus price target of $6.00, indicating a potential upside of 631.71%. Given Dyadic International's stronger consensus rating and higher probable upside, research analysts clearly believe Dyadic International is more favorable than Mustang Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyadic International
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Mustang Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Dyadic International beats Mustang Bio on 9 of the 15 factors compared between the two stocks.

Get Mustang Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBIO vs. The Competition

MetricMustang BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.44M$3.03B$5.54B$9.82B
Dividend YieldN/A2.27%4.62%4.12%
P/E Ratio-0.0220.6730.1326.03
Price / SalesN/A365.02462.16104.73
Price / CashN/A42.0537.7558.93
Price / Book2.837.638.496.06
Net Income-$15.75M-$54.65M$3.26B$265.11M
7 Day Performance23.03%5.41%4.19%3.38%
1 Month Performance-22.73%7.14%4.65%2.28%
1 Year Performance-88.67%31.27%35.15%29.67%

Mustang Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBIO
Mustang Bio
0.3987 of 5 stars
$1.87
+10.0%
N/A-89.5%$7.44MN/A-0.02100Positive News
Earnings Report
DYAI
Dyadic International
3.1557 of 5 stars
$0.81
-13.6%
$6.00
+640.8%
-39.3%$28.19M$3.49M-4.057News Coverage
Earnings Report
MAAQ
Mana Capital Acquisition
N/A$3.45
-10.9%
N/A+790.5%$28.03MN/A0.001High Trading Volume
GBIO
Generation Bio
3.7699 of 5 stars
$4.04
-1.5%
$80.00
+1,880.2%
-73.9%$27.62M$19.89M-0.37150News Coverage
Earnings Report
Analyst Forecast
Gap Up
OKUR
OnKure Therapeutics
3.2734 of 5 stars
$2.03
-0.5%
$32.33
+1,492.8%
N/A$27.56MN/A-0.39N/AEarnings Report
Gap Up
MURA
Mural Oncology
3.1658 of 5 stars
$1.55
-2.5%
$12.00
+674.2%
-42.4%$27.55MN/A-0.18119Gap Up
High Trading Volume
TPST
Tempest Therapeutics
3.092 of 5 stars
$8.01
+8.8%
$30.00
+274.5%
-34.7%$27.10MN/A-0.4520Positive News
Earnings Report
MDCX
Medicus Pharma
2.0735 of 5 stars
$1.97
flat
$23.50
+1,092.9%
N/A$26.74MN/A-1.70N/AEarnings Report
Analyst Forecast
BDRX
Biodexa Pharmaceuticals
0.2001 of 5 stars
$6.89
-3.4%
N/AN/A$26.06M$470K0.0020Positive News
RNTX
Rein Therapeutics
N/A$1.16
+4.5%
N/AN/A$25.58MN/A-0.419
NNVC
NanoViricides
0.268 of 5 stars
$1.54
-2.5%
N/A-13.8%$24.75MN/A-2.1420

Related Companies and Tools


This page (NASDAQ:MBIO) was last updated on 8/14/2025 by MarketBeat.com Staff
From Our Partners